 Immunohistochemical study androgen receptors metastatic prostate cancer Comparison receptor content response hormonal therapy longstanding goal androgen receptor AR levels clinical response metastatic prostate cancer withdrawal therapy major limitation previous studies use homogenized tissue average AR content cells AR immunohistochemical study antibody specific AR authors nuclear AR content malignant epithelial cells prostate needle biopsy specimens patients Stage prostate cancer authors prostate cancer AR-positive AR-negative malignant cells androgen withdrawal therapy percentage AR-positive cells time progression therapy significant correlation percentage AR-positive malignant cells time progression patients groups median time progression percentage AR-positive nuclei different poor responders good responders patients groups median percentage receptor-positive nuclei Kaplan-Meier estimates progression-free interval significant difference group patients AR-poor tumors patients AR-rich tumors Potential explanations results authors percentage AR-positive nuclei sufficient criterion tumor behavior